{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:21:29Z","timestamp":1787505689493,"version":"build-2736575974"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","award":["1004\/22"],"award-info":[{"award-number":["1004\/22"]}],"id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nutr. Diabetes"],"DOI":"10.1038\/s41387-025-00398-3","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T16:21:37Z","timestamp":1761582097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Non-carbohydrate anaplerotic therapy counters empagliflozin-induced diabetic ketosis"],"prefix":"10.1038","volume":"15","author":[{"given":"Jimmy","family":"Asiku","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mugagga","family":"Kalyesubula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Rosov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5024-5626","authenticated-orcid":false,"given":"Hay","family":"Dvir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"398_CR1","doi-asserted-by":"publisher","unstructured":"Cryer PE. Glycemic goals in diabetes: Trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes. 2014. https:\/\/doi.org\/10.2337\/db14-0059.","DOI":"10.2337\/db14-0059"},{"key":"398_CR2","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/dme.13941","volume":"36","author":"LA Wright","year":"2019","unstructured":"Wright LA, Hirsch IB. Non-insulin treatments for Type 1 diabetes: critical appraisal of the available evidence and insight into future directions. Diabet Med. 2019;36:665\u201378.","journal-title":"Diabet Med"},{"key":"398_CR3","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.2337\/dci24-0032","volume":"47","author":"GE Umpierrez","year":"2024","unstructured":"Umpierrez GE, Davis GM, Elsayed NA, Fadini GP, Galindo RJ, Hirsch IB, et al. Hyperglycemic crises in adults with diabetes: a consensus report. Diabetes Care. 2024;47:1257\u201375.","journal-title":"Diabetes Care"},{"key":"398_CR4","doi-asserted-by":"publisher","unstructured":"Weinstock RS, Xing D, Maahs DM, Michels A, Rickels MR, Peters AL et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: Results from the T1D exchange clinic registry. J Clin Endocrinol Metab. 2013. https:\/\/doi.org\/10.1210\/jc.2013-1589.","DOI":"10.1210\/jc.2013-1589"},{"key":"398_CR5","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.metabol.2015.12.007","volume":"65","author":"EA Nyenwe","year":"2016","unstructured":"Nyenwe EA, Kitabchi AE. The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism. 2016;65:507\u201321.","journal-title":"Metabolism"},{"key":"398_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1146\/annurev.bi.49.070180.002143","volume":"49","author":"JD McGarry","year":"1980","unstructured":"McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem. 1980;49:395\u2013420.","journal-title":"Annu Rev Biochem"},{"key":"398_CR7","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2337\/diab.30.9.781","volume":"30","author":"ML Halperin","year":"1981","unstructured":"Halperin ML, Bear RA, Hannaford MC, Goldstein MB. Selected aspects of the pathophysiology of metabolic acidosis in diabetes mellitus. Diabetes. 1981;30:781\u20137.","journal-title":"Diabetes"},{"key":"398_CR8","doi-asserted-by":"publisher","unstructured":"Puchalska P, Crawford PA. Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics. Cell Metab. 2017. https:\/\/doi.org\/10.1016\/j.cmet.2016.12.022.","DOI":"10.1016\/j.cmet.2016.12.022"},{"key":"398_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.freeradbiomed.2016.03.020","volume":"95","author":"P Kanikarla-Marie","year":"2016","unstructured":"Kanikarla-Marie P, Jain SK. Hyperketonemia and ketosis increase the risk of complications in type 1 diabetes. Free Radic Biol Med. 2016;95:268\u201377.","journal-title":"Free Radic Biol Med"},{"key":"398_CR10","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1172\/JCI112981","volume":"79","author":"L Rossetti","year":"1987","unstructured":"Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissues sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510\u20135.","journal-title":"J Clin Invest"},{"key":"398_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-019-0828-y","volume":"18","author":"CMA Cefalo","year":"2019","unstructured":"Cefalo CMA, Cinti F, Moffa S, Impronta F, Sorice GP, Mezza T, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019;18:1\u201314.","journal-title":"Cardiovasc Diabetol"},{"key":"398_CR12","first-page":"92","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala L. Jardiance (Empagliflozin), an SGLT2 inhibitor, receives FDA approval for the treatment of patients with type 2 diabetes. Am Heal drug benefits. 2015;8:92\u20135.","journal-title":"Am Heal drug benefits"},{"key":"398_CR13","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1590\/1806-9282.63.07.636","volume":"63","author":"LL Santos","year":"2017","unstructured":"Santos LL, De Lima FJC, De Sousa-Rodrigues CF, Barbosa FT. Use of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. Rev Assoc Med Bras. 2017;63:636\u201341.","journal-title":"Rev Assoc Med Bras"},{"key":"398_CR14","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1007\/s00125-018-4671-6","volume":"61","author":"RJ McCrimmon","year":"2018","unstructured":"McCrimmon RJ, Henry RR. SGLT inhibitor adjunct therapy in type 1 diabetes. Diabetologia. 2018;61:2126\u201333.","journal-title":"Diabetologia"},{"key":"398_CR15","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.2337\/dc18-2316","volume":"42","author":"T Danne","year":"2019","unstructured":"Danne T, Garg S, Peters AL, Buse JB, Mathieu C, Pettus JH, et al. International consensus on risk management of diabetic ketoacidosis in patients with type 1 diabetes treated with sodium-glucose cotransporter (SGLT) inhibitors. Diabetes Care. 2019;42:1147\u201354.","journal-title":"Diabetes Care"},{"key":"398_CR16","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.2337\/dc18-1749","volume":"41","author":"J Rosenstock","year":"2018","unstructured":"Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, et al. Empagliflozin as adjunctive to insulin therapyin type 1 diabetes: The EASE trials. Diabetes Care. 2018;41:2560\u20139.","journal-title":"Diabetes Care"},{"key":"398_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/omcr\/omw061","volume":"2016","author":"N Candelario","year":"2016","unstructured":"Candelario N, Wykretowicz J. The DKA that wasn\u2019t: a case of euglycemic diabetic ketoacidosis due to empagliflozin. Oxford Med Case Rep. 2016;2016:144\u20136.","journal-title":"Oxford Med Case Rep."},{"key":"398_CR18","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.2337\/dc15-1797","volume":"39","author":"P Roach","year":"2016","unstructured":"Roach P, Skierczynski P. Euglycemic diabetic ketoacidosis in a patient with type 2 diabetes after treatment with empagliflozin. Diabetes Care. 2016;39:e3.","journal-title":"Diabetes Care"},{"key":"398_CR19","doi-asserted-by":"crossref","unstructured":"Modi A, Agrawal A, Morgan F. Euglycemic diabetic ketoacidosis: a review. Curr Diabetes Rev. 2016;13:315\u201321.","DOI":"10.2174\/1573399812666160421121307"},{"key":"398_CR20","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.2337\/dc15-0843","volume":"38","author":"AL Peters","year":"2015","unstructured":"Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38:1687\u201393.","journal-title":"Diabetes Care"},{"key":"398_CR21","first-page":"1","volume":"2","author":"Research C for DE and..","year":"2020","unstructured":"Research C for DE and.. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. Fda. 2020;2:1\u20138.","journal-title":"Fda"},{"key":"398_CR22","unstructured":"Food and Drug Administration US. FDA Drug Safety Communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. FDA Drug Saf Commun. 2015. http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm475463.htm."},{"key":"398_CR23","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","volume":"60","author":"GP Fadini","year":"2017","unstructured":"Fadini GP, Bonora BM, Avogaro A. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017;60:1385\u20139.","journal-title":"Diabetologia"},{"key":"398_CR24","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1007\/s00125-022-05773-8","volume":"65","author":"E Marilly","year":"2022","unstructured":"Marilly E, Cottin J, Cabrera N, Cornu C, Boussageon R, Moulin P, et al. SGLT2 inhibitors in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials balancing their risks and benefits. Diabetologia. 2022;65:2000\u201310.","journal-title":"Diabetologia"},{"key":"398_CR25","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/jc.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849\u201352.","journal-title":"J Clin Endocrinol Metab"},{"key":"398_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1042\/bj0720087","volume":"72","author":"SJ BACH","year":"1959","unstructured":"BACH SJ, HIBBITT KG. Biochemical aspects of bovine ketosis. Biochem J. 1959;72:87\u201392.","journal-title":"Biochem J"},{"key":"398_CR27","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3390\/ani5030384","volume":"5","author":"H White","year":"2015","unstructured":"White H. The role of TCA cycle anaplerosis in ketosis and fatty liver in periparturient dairy cows. Animals. 2015;5:793\u2013802.","journal-title":"Animals"},{"key":"398_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/(SICI)1520-7560(199911\/12)15:6<412::AID-DMRR72>3.0.CO;2-8","volume":"15","author":"L Laffel","year":"1999","unstructured":"Laffel L. Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 1999;15:412\u201326.","journal-title":"Diabetes Metab Res Rev"},{"key":"398_CR29","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.cmet.2019.03.014","volume":"29","author":"DA Cappel","year":"2019","unstructured":"Cappel DA, Deja S, Duarte JAG, Kucejova B, I\u00f1igo M, Fletcher JA, et al. Pyruvate-carboxylase-mediated anaplerosis promotes antioxidant capacity by sustaining TCA cycle and redox metabolism in liver. Cell Metab. 2019;29:1291\u2013.e8.","journal-title":"Cell Metab"},{"key":"398_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1111\/jdi.12401","volume":"7","author":"W Ogawa","year":"2016","unstructured":"Ogawa W, Sakaguchi K. Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: Possible mechanism and contributing factors. J Diabetes Investig. 2016;7:135\u20138.","journal-title":"J Diabetes Investig"},{"key":"398_CR31","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nrendo.2016.15","volume":"12","author":"G Umpierrez","year":"2016","unstructured":"Umpierrez G, Korytkowski M. Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12:222\u201332.","journal-title":"Nat Rev Endocrinol"},{"key":"398_CR32","doi-asserted-by":"publisher","unstructured":"du Sert NP, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The arrive guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020. https:\/\/doi.org\/10.1371\/journal.pbio.3000410.","DOI":"10.1371\/journal.pbio.3000410"},{"key":"398_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0008-6363(02)00468-6","volume":"55","author":"HF del Valle","year":"2002","unstructured":"del Valle HF, Lascano EC, Negroni JA. Ischemic preconditioning protection against stunning in conscious diabetic sheep: role of glucose, insulin, sarcolemmal and mitochondrial KATP channels. Cardiovasc Res. 2002;55:642\u201359.","journal-title":"Cardiovasc Res"},{"key":"398_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/0005-2760(82)90154-0","volume":"710","author":"GD Henderson","year":"1982","unstructured":"Henderson GD, Read LC, Snoswell AM. Studies of liver lipids in normal, alloxan-diabetic and pregnancy-toxaemic sheep. Biochim Biophys Acta (BBA)\/Lipids Lipid Metab. 1982;710:236\u201341.","journal-title":"Biochim Biophys Acta (BBA)\/Lipids Lipid Metab"},{"key":"398_CR35","first-page":"149","volume":"4","author":"S Kazemi-Darabadi","year":"2013","unstructured":"Kazemi-Darabadi S, Sarrafzadeh-Rezaei F, Farshid AA, Baradar-Jalili R. Healing of excisional wound in alloxan induced diabetic sheep: a planimetric and histopathologic study. Vet Res Forum. 2013;4:149\u201355.","journal-title":"Vet Res Forum"},{"key":"398_CR36","doi-asserted-by":"publisher","unstructured":"Leenanuruksa D, Mc Dowell GH. Experimental diabetes in lactating sheep: Effects of alloxan on plasma insulin, glucose, glucose kinetics and milk characteristics. Aust J Biol Sci. 1988. https:\/\/doi.org\/10.1071\/BI9880223.","DOI":"10.1071\/BI9880223"},{"key":"398_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1152\/ajplegacy.1948.154.1.94","volume":"154","author":"EL McCandless","year":"1948","unstructured":"McCandless EL, Woodward BA, DYE JA. Alloxan diabetes in sheep under fasting and non-fasting conditions. Am J Physiol. 1948;154:94\u2013106.","journal-title":"Am J Physiol"},{"key":"398_CR38","doi-asserted-by":"publisher","first-page":"S13","DOI":"10.2337\/dc18-S002","volume":"41","author":"D Care","year":"2018","unstructured":"Care D, Suppl SS. Classification and diagnosis of diabetes: standards of medical care in diabetes. Diabetes Care. 2018;41:S13\u2013S27.","journal-title":"Diabetes Care"},{"key":"398_CR39","doi-asserted-by":"publisher","unstructured":"Council NR Nutrient Requirements of Small Ruminants. National Academies Press: Washington, D.C., 2007 https:\/\/doi.org\/10.17226\/11654.","DOI":"10.17226\/11654"},{"key":"398_CR40","doi-asserted-by":"publisher","unstructured":"Kalyesubula M, Rosov A, Alon T, Moallem U, Dvir H. Intravenous infusions of glycerol versus propylene glycol for the regulation of negative energy balance in sheep: a randomized trial. Animals. 2019;9. https:\/\/doi.org\/10.3390\/ani9100731.","DOI":"10.3390\/ani9100731"},{"key":"398_CR41","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0300-595X(83)80043-7","volume":"12","author":"JM Miles","year":"1983","unstructured":"Miles JM, Gerich JE. Glucose and ketone body kinetics in diabetic ketoacidosis. Clin Endocrinol Metab. 1983;12:303\u201319.","journal-title":"Clin Endocrinol Metab"},{"key":"398_CR42","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1146\/annurev.bi.46.070177.004001","volume":"46","author":"ECC Lin","year":"1977","unstructured":"Lin ECC. Glycerol utilization and its regulation in mammals. Annu Rev Biochem. 1977;46:765\u201395.","journal-title":"Annu Rev Biochem"},{"key":"398_CR43","doi-asserted-by":"publisher","first-page":"3311","DOI":"10.3168\/jds.2008-0997","volume":"91","author":"MA Osman","year":"2008","unstructured":"Osman MA, Allen PS, Mehyar NA, Bobe G, Coetzee JF, Koehler KJ, et al. Acute metabolic responses of postpartal dairy cows to subcutaneous glucagon injections, oral glycerol, or both. J Dairy Sci. 2008;91:3311\u201322.","journal-title":"J Dairy Sci"},{"key":"398_CR44","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1111\/jpn.12245","volume":"99","author":"A Werner Omazic","year":"2015","unstructured":"Werner Omazic A, Kronqvist C, Zhongyan L, Martens H, Holtenius K. The fate of glycerol entering the rumen of dairy cows and sheep. J Anim Physiol Anim Nutr (Berl). 2015;99:258\u201364.","journal-title":"J Anim Physiol Anim Nutr (Berl)"},{"key":"398_CR45","doi-asserted-by":"crossref","unstructured":"Burgess N, Inigo M, Deja S, Burgess SC. Ins and outs of the TCA cycle: the central role of anaplerosis. 2021;41:19\u201347.","DOI":"10.1146\/annurev-nutr-120420-025558"},{"key":"398_CR46","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1016\/S0021-9258(18)93669-0","volume":"244","author":"JR Williamson","year":"1969","unstructured":"Williamson JR, Scholz R, Browning ET. Control mechanisms of gluconeogenesis and ketogenesis. II. Interactions between fatty acid oxidation and the citric acid cycle in perfused rat liver. J Biol Chem. 1969;244:4617\u201327.","journal-title":"J Biol Chem"},{"key":"398_CR47","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1002\/j.2040-4603.2014.tb00548.x","volume":"4","author":"L Rui","year":"2014","unstructured":"Rui L. Energy metabolism in the liver. Compr Physiol. 2014;4:177\u201397.","journal-title":"Compr Physiol"},{"key":"398_CR48","doi-asserted-by":"publisher","first-page":"18621","DOI":"10.1074\/jbc.272.30.18621","volume":"272","author":"RJ Noel","year":"1997","unstructured":"Noel RJ, Antinozzi PA, McGarry JD, Newgard CB. Engineering of glycerol-stimulated insulin secretion in islet beta cells. J Biol Chem. 1997;272:18621\u20137.","journal-title":"J Biol Chem"},{"key":"398_CR49","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.2337\/diabetes.50.8.1791","volume":"50","author":"RH Skelly","year":"2001","unstructured":"Skelly RH, Wicksteed B, Antinozzi PA, Rhodes CJ. Glycerol-stimulated proinsulin biosynthesis in isolated pancreatic rat islets via adenoviral-induced expression of glycerol kinase is mediated via mitochondrial metabolism. Diabetes. 2001;50:1791\u20138.","journal-title":"Diabetes"},{"key":"398_CR50","doi-asserted-by":"publisher","first-page":"425","DOI":"10.4103\/0259-1162.176411","volume":"10","author":"R Khetarpal","year":"2016","unstructured":"Khetarpal R, Chatrath V, Kaur J, Bala A, Singh H. Impact of different intravenous fluids on blood glucose levels in nondiabetic patients undergoing elective major noncardiac surgeries. Anesth essays Res. 2016;10:425\u201331.","journal-title":"Anesth essays Res"},{"key":"398_CR51","doi-asserted-by":"publisher","unstructured":"Koschinsky T, Gries FA, Herberg L. Regulation of glycerol kinase by insulin in isolated fat cells and liver of Bar Harbor Obese Mice. Diabetologia. 1971. https:\/\/doi.org\/10.1007\/BF01219464.","DOI":"10.1007\/BF01219464"},{"key":"398_CR52","doi-asserted-by":"publisher","first-page":"2C","DOI":"10.1042\/bj1040002C","volume":"104","author":"J Robinson","year":"1967","unstructured":"Robinson J, Newsholme EA. Glycerol kinase activities in rat heart and adipose tissue. Biochem J. 1967;104:2C\u20134C.","journal-title":"Biochem J"},{"key":"398_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ani10081379","volume":"10","author":"R Kupczy\u0144ski","year":"2020","unstructured":"Kupczy\u0144ski R, Szumny A, Wujcikowska K, Pachura N. Metabolism, ketosis treatment and milk production after using glycerol in dairy cows: A review. Animals. 2020;10:1\u201317.","journal-title":"Animals"},{"key":"398_CR54","first-page":"875","volume":"95","author":"DM Polizel","year":"2017","unstructured":"Polizel DM, Susin I, Gentil RS, Ferreira EM, de Souza RA, Freire APA, et al. Crude glycerin decreases nonesterified fatty acid concentration in ewes during late gestation and early lactation. J Anim Sci. 2017;95:875\u201383.","journal-title":"J Anim Sci"},{"key":"398_CR55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.anifeedsci.2016.01.010","volume":"213","author":"SM Ferraro","year":"2016","unstructured":"Ferraro SM, Mendoza GD, Miranda LA, Guti\u00e9rrez CG. In vitro ruminal fermentation of glycerol, propylene glycol and molasses combined with forages and their effect on glucose and insulin blood plasma concentrations after an oral drench in sheep. Anim Feed Sci Technol. 2016;213:74\u201380.","journal-title":"Anim Feed Sci Technol"},{"key":"398_CR56","doi-asserted-by":"publisher","first-page":"10245","DOI":"10.3168\/jds.2020-18227","volume":"103","author":"T Alon","year":"2020","unstructured":"Alon T, Rosov A, Lifshitz L, Dvir H, Gootwine E, Moallem U. The distinctive short-term response of late-pregnant prolific ewes to propylene glycol or glycerol drenching. J Dairy Sci. 2020;103:10245\u201357.","journal-title":"J Dairy Sci"},{"key":"398_CR57","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2147\/DMSO.S250699","volume":"13","author":"J Zhao","year":"2020","unstructured":"Zhao J, Wu Y, Rong X, Zheng C, Guo J. Anti-lipolysis induced by insulin in diverse pathophysiologic conditions of adipose tissue. Diabetes, Metab Syndr Obes Targets Ther. 2020;13:1575\u201385.","journal-title":"Diabetes, Metab Syndr Obes Targets Ther"},{"key":"398_CR58","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1146\/annurev.nutr.27.061406.093734","volume":"27","author":"RE Duncan","year":"2007","unstructured":"Duncan RE, Ahmadian M, Jaworski K, Sarkadi-Nagy E, Sul HS. Regulation of lipolysis in adipocytes. Annu Rev Nutr. 2007;27:79\u2013101.","journal-title":"Annu Rev Nutr"},{"key":"398_CR59","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1016\/0026-0495(79)90215-4","volume":"28","author":"DS Schade","year":"1979","unstructured":"Schade DS, Woodside W, Eaton RP. The role of glucagon in the regulation of plasma lipids. Metabolism. 1979;28:874\u201386.","journal-title":"Metabolism"},{"key":"398_CR60","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.peptides.2017.11.013","volume":"100","author":"RV Scott","year":"2018","unstructured":"Scott RV, Bloom S. Problem or solution: the strange story of glucagon. Peptides. 2018;100:36\u201341.","journal-title":"Peptides"}],"container-title":["Nutrition &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41387-025-00398-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-025-00398-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41387-025-00398-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:14:18Z","timestamp":1761628458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41387-025-00398-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["398"],"URL":"https:\/\/doi.org\/10.1038\/s41387-025-00398-3","relation":{},"ISSN":["2044-4052"],"issn-type":[{"value":"2044-4052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"1 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"HD filed for a US patent application entitled \u201cMethods for preventing or treating diabetic and non-diabetic ketoacidosis\u201d. PCT\/IL2019\/051207.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42"}}